Rheumatology

Rheumatoid Arthritis: The Pannus and Citrullination Cascade

By the time a patient with rheumatoid arthritis (RA) walks into clinic, their own immune system has often been attacking their joints silently for a decade — anti-citrullinated protein antibodies (ACPAs) can appear in the blood up to 10 years before the first swollen knuckle. RA is a chronic, symmetric, immune-mediated polyarthritis affecting roughly 0.5–1% of adults worldwide, with a 2–3:1 female predominance, in which a self-perpetuating inflammatory membrane called pannus invades and destroys the joint.

The disease is not simply "wear and tear." It is a systemic autoimmune process driven by a break in tolerance to citrullinated self-proteins, orchestrated by T cells, B cells, fibroblast-like synoviocytes, and a cytokine storm dominated by TNF-α, IL-6, and IL-1. Left untreated, the pannus erodes cartilage and bone, producing the classic deforming hand changes that once defined the disease.

  • MechanismLoss of tolerance to citrullinated proteins → ACPA/RF immune complexes → synovial pannus
  • Classic signSymmetric small-joint (MCP, PIP, wrist) synovitis with >60 min morning stiffness
  • Key testAnti-CCP (ACPA) antibody + rheumatoid factor; elevated ESR/CRP
  • Diagnostic tool2010 ACR/EULAR classification score ≥6 of 10
  • First-line treatmentMethotrexate (anchor DMARD), often + short-term glucocorticoid bridge
  • Main complicationJoint erosion/deformity; accelerated cardiovascular disease is the leading cause of death

Interactive visualization

Press play, or step through manually. The visualization is yours to drive — try it before reading on.

Open visualization fullscreen ↗

Watch the 60-second explainer

A condensed visual walkthrough — narrated, captioned, under a minute.

What Rheumatoid Arthritis Is and Why It Matters

Rheumatoid arthritis is a chronic systemic autoimmune disease whose principal target is the synovium — the thin membrane lining diarthrodial joints. Unlike osteoarthritis, a degenerative "mechanical" disorder, RA is an inflammatory disease in which immune cells actively destroy cartilage and bone.

  • Epidemiology: prevalence ~0.5–1% of adults; peak onset 30–60 years; women affected 2–3× more than men.
  • Genetics: the strongest risk is the HLA-DRB1 "shared epitope" (a conserved amino-acid motif at positions 70–74). PTPN22 and PADI4 polymorphisms also confer risk.
  • Environment: cigarette smoking is the dominant modifiable trigger and interacts with the shared epitope to drive citrullination. Periodontal disease (Porphyromonas gingivalis, which carries its own citrullinating enzyme) is also implicated.

It matters clinically because RA is not confined to joints: it accelerates atherosclerosis, causes interstitial lung disease, and shortens life expectancy. Cardiovascular disease — not joint failure — is the leading cause of death.

The Mechanism: Citrullination and the Pannus Cascade

The molecular engine of RA is citrullination. Enzymes called peptidyl arginine deiminases (PAD2/PAD4) convert peptidyl-arginine to peptidyl-citrulline, a post-translational change that neutralizes a positive charge and alters protein shape. In genetically susceptible people, these modified self-proteins (citrullinated vimentin, fibrinogen, α-enolase, type II collagen) are presented on HLA-DR shared-epitope molecules to CD4+ T cells.

  • Break in tolerance: T-helper cells activate B cells, which produce anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (an antibody against the Fc portion of IgG).
  • Immune complexes deposit in synovium, activating the complement cascade and macrophages.
  • Cytokine storm: macrophages and fibroblast-like synoviocytes pour out TNF-α, IL-6, and IL-1, amplifying inflammation and recruiting more leukocytes.

The synovium hypertrophies into an invasive, tumor-like tissue — the pannus — rich in fibroblast-like synoviocytes and neovessels. TNF/IL-6-driven RANKL expression activates osteoclasts, while matrix metalloproteinases digest cartilage. The result is the marginal bony erosion seen on radiographs.

Clinical Presentation and Classic Signs

RA classically presents as an insidious, symmetric polyarthritis of the small joints. Patients report:

  • Morning stiffness lasting >60 minutes that improves with movement (an inflammatory pattern, opposite to osteoarthritis).
  • Symmetric swelling and tenderness of the metacarpophalangeal (MCP), proximal interphalangeal (PIP), and wrist joints — RA characteristically spares the distal interphalangeal (DIP) joints.
  • Constitutional symptoms: fatigue, low-grade fever, weight loss.

Chronic uncontrolled disease produces the classic deformities: ulnar deviation of the fingers at the MCPs, swan-neck deformity (PIP hyperextension, DIP flexion), boutonnière deformity (PIP flexion, DIP hyperextension), and Z-thumb.

Extra-articular features include rheumatoid nodules over extensor surfaces, interstitial lung disease, secondary Sjögren syndrome, and Felty syndrome (RA + splenomegaly + neutropenia). A critical do-not-miss finding is atlantoaxial subluxation of the cervical spine, which threatens the spinal cord during intubation.

Diagnosis: Serology, Criteria, and Imaging

RA is a clinical diagnosis supported by serology, inflammatory markers, and imaging; there is no single confirmatory test. The 2010 ACR/EULAR classification criteria score four domains, and a total ≥6 of 10 classifies definite RA:

  • Joint involvement (0–5 points): more/smaller joints score higher.
  • Serology (0–3): high-titer RF or anti-CCP scores most.
  • Acute-phase reactants (0–1): abnormal ESR or CRP.
  • Symptom duration (0–1): ≥6 weeks.

Anti-CCP (ACPA) is the key antibody: sensitivity ~60–70% but specificity ~95%, making it far more specific than rheumatoid factor (RF), which is also positive in hepatitis C, Sjögren, and endocarditis. Anti-CCP positivity predicts erosive, aggressive disease.

Imaging: plain radiographs show soft-tissue swelling, juxta-articular (periarticular) osteopenia, symmetric joint-space narrowing, and marginal erosions. MRI and ultrasound (with power Doppler for synovitis) detect erosions and active inflammation earlier than X-ray, enabling early treatment.

Management at a Mechanism Level

The modern strategy is "treat-to-target": escalate therapy until remission or low disease activity (measured by scores such as DAS28), because early aggressive control prevents irreversible erosion.

  • Methotrexate is the anchor conventional DMARD — a dihydrofolate reductase inhibitor whose anti-inflammatory effect derives largely from adenosine accumulation. Give with folic acid; monitor for hepatotoxicity, cytopenias, and pneumonitis. It is a teratogen (contraindicated in pregnancy).
  • Biologic DMARDs target the cascade directly: TNF inhibitors (adalimumab, etanercept, infliximab), IL-6 receptor blockade (tocilizumab), B-cell depletion (rituximab, anti-CD20), and T-cell co-stimulation blockade (abatacept, CTLA-4-Ig).
  • Targeted synthetic DMARDs: JAK inhibitors (tofacitinib, baricitinib) block intracellular cytokine signaling.
  • Glucocorticoids serve as a short-term "bridge" while DMARDs take effect (weeks to months); NSAIDs give symptomatic relief only and do not alter progression.

Before starting biologics, screen for latent tuberculosis and hepatitis B, because TNF blockade can reactivate them — a classic do-not-miss pitfall.

Mimics, Pitfalls, and Clinical Significance

Distinguishing RA from its mimics changes both prognosis and treatment. Osteoarthritis spares the wrist and MCPs, hits the DIPs (Heberden nodes), causes brief (<30-minute) stiffness that worsens with use, and is seronegative with normal inflammatory markers. Psoriatic arthritis and the other seronegative spondyloarthropathies are RF/ACPA-negative and feature enthesitis, dactylitis, and DIP disease. Systemic lupus can cause a symmetric arthritis, but its Jaccoud arthropathy is non-erosive and reducible.

  • Do-not-miss: a new hot, single joint in an RA patient is septic arthritis until proven otherwise — arthrocentesis is mandatory, since immunosuppression masks infection.
  • Pitfall: RF is not specific; ordering it as a screen in low-probability patients yields false positives.
  • Significance: the greatest killer is accelerated cardiovascular disease, driven by systemic inflammation — controlling RA also lowers cardiac risk.

The unifying insight: RA is a citrullination-driven autoimmune synovitis, and stopping the pannus early is what preserves the joint.

Rheumatoid arthritis vs. common arthritis mimics
FeatureRheumatoid arthritisOsteoarthritisPsoriatic arthritis
Joint distributionSymmetric MCP/PIP, wrists (spares DIP)DIP/PIP, hips, knees, spine; asymmetricAsymmetric, DIP involvement, dactylitis
Morning stiffness>60 min, improves with activity<30 min, worsens with useProlonged, with enthesitis
Key serologyAnti-CCP (ACPA) + RF positiveSeronegativeSeronegative (RF/ACPA negative)
Inflammatory markersESR/CRP elevatedNormalOften elevated
Characteristic X-rayMarginal erosions, juxta-articular osteopeniaOsteophytes, subchondral sclerosis, joint-space narrowing'Pencil-in-cup' deformity
Nodules/skinRheumatoid nodules (extensor surfaces)Heberden/Bouchard nodes (bony)Psoriatic plaques, nail pitting

Frequently asked questions

What is the difference between rheumatoid arthritis and osteoarthritis?

Rheumatoid arthritis is an autoimmune inflammatory disease that symmetrically attacks the small joints (MCPs, PIPs, wrists), causes morning stiffness lasting over an hour, and is associated with anti-CCP antibodies and elevated ESR/CRP. Osteoarthritis is a degenerative 'wear-and-tear' condition that hits weight-bearing joints and DIPs, causes brief stiffness that worsens with use, and shows normal inflammatory markers. RA erodes bone; osteoarthritis produces osteophytes.

What is a pannus in rheumatoid arthritis?

The pannus is the abnormal, invasive inflammatory tissue that forms when the synovial membrane hypertrophies in RA. It behaves like a locally invasive tumor, packed with activated fibroblast-like synoviocytes, macrophages, and new blood vessels. Driven by TNF-α and IL-6, the pannus releases matrix metalloproteinases and activates osteoclasts (via RANKL), directly eroding the cartilage and bone at the joint margins.

How specific is the anti-CCP (ACPA) test for rheumatoid arthritis?

Anti-cyclic citrullinated peptide (anti-CCP/ACPA) antibody has a sensitivity of roughly 60–70% but a high specificity of about 95%, making it much more specific than rheumatoid factor. A positive anti-CCP strongly supports RA and predicts a more erosive, aggressive disease course. It can appear in the blood years before symptoms begin, making it valuable for early identification.

Why is smoking such a strong risk factor for rheumatoid arthritis?

Cigarette smoke induces peptidyl arginine deiminase (PAD) activity in the lungs, increasing citrullination of self-proteins. In people carrying the HLA-DRB1 'shared epitope,' these citrullinated proteins are efficiently presented to T cells, triggering ACPA production. The gene–environment interaction between smoking and the shared epitope multiplies RA risk far beyond either factor alone, and smoking also worsens disease severity and blunts treatment response.

Why is methotrexate the first-line drug for rheumatoid arthritis?

Methotrexate is the anchor DMARD because it reliably slows joint erosion, is inexpensive, and combines well with biologics. Although it inhibits dihydrofolate reductase, its anti-inflammatory benefit in RA comes mainly from promoting adenosine release, which dampens immune activation. It is given weekly with folic acid to reduce side effects; patients need monitoring for liver toxicity, low blood counts, and rare pneumonitis, and it must be avoided in pregnancy.

What must be checked before starting a TNF inhibitor?

Before starting a TNF inhibitor (adalimumab, etanercept, infliximab) or other biologic, clinicians must screen for latent tuberculosis (with a TB skin test or interferon-gamma release assay and chest X-ray) and for hepatitis B, because blocking TNF-α can reactivate dormant infection. Live vaccines should also be updated beforehand. Missing latent TB screening is a classic, dangerous pitfall.